Glycols as pathogen inactivating agents
View Patent ↗The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.
1. A method for inactivating and/or eliminating an enveloped virus for the production of a recombinant protein, said method comprising conducting affinity chromatography on a biological composition containing a recombinant protein, wherein the recombinant protein is eluted during the affinity chromatography with an elution buffer comprising propylene glycol, wherein the biological composition is a blood composition, a milk composition, urine, sweat, sputum, feces, spinal fluid, or cellular or tissue extracts, wherein the concentration of propylene glycol in the elution buffer is between 40 and 50% (v/v), and wherein the propylene glycol is not combined with arginine.
2. The method of claim 1 , wherein said method is performed at a temperature between 15 and 25° C.
3. The method of claim 1 , wherein said method is performed at a pH between 7.0 and 8.0.
4. The method of claim 1 , wherein the affinity chromatography column is washed with a wash buffer prior to elution of the recombinant protein, wherein the concentration of propylene glycol in the wash buffer is between 30 and 40% (v/v).
5. The method of claim 1 , wherein recombinant protein is maintained in the elution buffer with a concentration of propylene glycol between 40 and 50% (v/v) for less than 6 hours.
6. A method for inactivating and/or eliminating a virus during a purification of a protein from a biological composition, said method comprising contacting said biological composition during the purification of the protein with a glycol to inactivate the virus, wherein the concentration of glycol after the contacting step is between 40 and 50% (v/v) of the biological composition, and wherein the glycol is not combined with arginine.
7. The method of claim 6 , wherein said glycol is propylene glycol.
8. The method of claim 6 , wherein said biological composition is a blood composition or a milk composition.
9. The method of claim 6 , wherein the virus is an enveloped virus.
10. The method of claim 6 , wherein said method results in a viral elimination equal or greater than 4 Log 10 TCID, wherein the TCID is according to the methods of Kärber and/or Spearman-Kärber.
11. The method of claim 6 , wherein said method is performed at a temperature between 15 and 25° C.
12. The method of claim 6 , wherein said method is performed at a pH between 7.0 and 8.0.
13. A method for inactivating a virus during the purification of a protein from a biological composition, said method comprising contacting an eluate with a glycol during the process of purification of the protein from the biological composition to inactivate and/or eliminate the virus, wherein the concentration of glycol after the contacting step is between 40 and 50% (v/v) of the elute, and wherein the glycol is not combined with arginine.
14. The method of claim 13 , wherein said glycol is propylene glycol.
15. The method of claim 13 , wherein said biological composition is a blood composition or a milk composition.
16. The method of claim 13 , wherein the virus is an enveloped virus.
17. The method of claim 16 , wherein said enveloped virus is selected from the group consisting of X-MuLV, PRV, BVDV and TGEV virus.
18. The method of claim 13 , wherein said method results in a viral elimination equal or greater than 4 Log 10 TCID, wherein the TCID is according to the methods of Kärber and/or Spearman-Kärber.
19. The method of claim 13 , wherein said method is performed at a temperature between 15 and 25° C.
20. The method of claim 13 , wherein said method is performed at a pH between 7.0 and 8.0.